EBACW (European Biotech Acquisition) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBACW European Biotech Acquisition Corp EBACW
22 GF Score
Price $0.52
View Full Analysis

What is European Biotech Acquisition DeferredTaxAndRevenue?

European Biotech Acquisition EBACW 22 DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2022. GuruFocus rates EBACW with a GF Score™ of 22/100.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

European Biotech Acquisition's current deferred tax and revenue for the quarter that ended in Dec. 2022 was $0.00 Mil.

European Biotech Acquisition DeferredTaxAndRevenue Related Terms

European Biotech Acquisition DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for European Biotech Acquisition's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition DeferredTaxAndRevenue Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
DeferredTaxAndRevenue
0.00 0.00

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
DeferredTaxAndRevenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
EBACW
22GF Score
European Biotech Acquisition Corp EBACW
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
European Biotech Acquisition (EBACW) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2022. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on European Biotech Acquisition.
Is European Biotech Acquisition's DeferredTaxAndRevenue too high?
European Biotech Acquisition's current DeferredTaxAndRevenue is $0.00 Mil. Overall, European Biotech Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does European Biotech Acquisition's DeferredTaxAndRevenue compare to CNTQ and LION?
European Biotech Acquisition's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Diversified Financial Services company?
A good DeferredTaxAndRevenue depends on the Diversified Financial Services industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on European Biotech Acquisition. European Biotech Acquisition's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Biotech Acquisition stock overvalued right now?
European Biotech Acquisition (EBACW) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. European Biotech Acquisition's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For European Biotech Acquisition (EBACW), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

European Biotech Acquisition Business Description

Address EPFL Innovation Park Building, Lausanne, CHE, 1015
European Biotech Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for EBACW

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price